Concinnity Genetics, an Edinburgh-based startup, has raised £3m in a seed round led by Eos Advisory with additional participation from Scottish Enterprise, Old College Capital, and Maven Capital Partners. Founded by Jessica Birt and Matthew Dale, the company focuses on developing unique RNA-based control systems for gene therapies. Its platform combines synthetic biology and AI to create solutions that enhance the safety of gene and cell therapies by allowing precise control even after dosing.
The company's systems address key safety challenges in gene therapy, enabling treatments to respond to and mitigate their own side effects. The new capital will support spinning out operations from the University of Edinburgh, developing three new control system programmes for cell and gene therapy applications, and furthering existing systems to secure industry partnerships.
